Ray Co., Ltd. (228670.KQ)
KRW 6250.0
(-2.5%)
KRW 6250.0
(-2.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 6.11 Billion KRW | -62.63% |
| 2022 | 16.2 Billion KRW | 378.41% |
| 2021 | 3.38 Billion KRW | -26.05% |
| 2020 | 4.58 Billion KRW | -64.38% |
| 2019 | 12.86 Billion KRW | 112.66% |
| 2018 | 6.04 Billion KRW | 210.78% |
| 2017 | 1.94 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -6.71 Billion KRW | -321.52% |
| 2024 Q2 | -18.79 Billion KRW | -151.14% |
| 2023 Q3 | 4 Billion KRW | 20.31% |
| 2023 Q4 | 3.03 Billion KRW | -24.32% |
| 2023 FY | 6.05 Billion KRW | -62.63% |
| 2023 Q2 | 3.33 Billion KRW | 177.19% |
| 2023 Q1 | -4.31 Billion KRW | -145.12% |
| 2022 Q2 | 3.33 Billion KRW | 457.11% |
| 2022 FY | 16.2 Billion KRW | 378.41% |
| 2022 Q4 | 9.56 Billion KRW | 125.51% |
| 2022 Q3 | 4.24 Billion KRW | 27.3% |
| 2022 Q1 | -933.06 Million KRW | 85.46% |
| 2021 FY | 3.38 Billion KRW | -26.05% |
| 2021 Q4 | -6.41 Billion KRW | -241.58% |
| 2021 Q3 | 4.53 Billion KRW | 0.0% |
| 2020 FY | 4.58 Billion KRW | -64.38% |
| 2019 FY | 12.86 Billion KRW | 112.66% |
| 2018 FY | 6.04 Billion KRW | 210.78% |
| 2017 FY | 1.94 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 142.82 Billion KRW | 95.716% |
| InBody Co.,Ltd | 44.46 Billion KRW | 86.241% |
| Curexo Inc. | 1.13 Billion KRW | -438.854% |
| Seegene, Inc. | -30 Billion KRW | 120.389% |
| i-SENS, Inc. | 10.92 Billion KRW | 44.019% |
| Gencurix Inc. | -12.37 Billion KRW | 149.437% |
| Sugentech Inc. | -22.74 Billion KRW | 126.903% |
| L&C Bio Co., Ltd | 6.66 Billion KRW | 8.227% |